2025-ASCO-Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 38) of the GSK-3 inhibitor elraglusib with gemcitabine/nab-paclitaxel (GnP) in metastatic pancreatic ductal adenocarcinoma (mPDAC): application toward patient enrichment
Wednesday, May 28, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses a phase 2 trial evaluating elraglusib, a GSK-3 inhibitor, in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma. It highlights the use of machine learning to predict overall survival based on pre-dose plasma biomarkers, aiming to improve patient enrichment strategies. This innovative approach could enhance treatment outcomes.
Price reaction · baseline $10.47 (2025-05-28T14:55:00.000Z) · hit during market hours · 3 other ACTU headline(s) in the window, move may be shared
day 0 close · peak
+3.1%
Market Sentiment Analysis
POSITIVE FACTORS
The study utilizes machine learning for predicting survival outcomes.
Elraglusib shows promise when combined with gemcitabine/nab-paclitaxel.
The trial aims to enhance patient selection for treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
9.4%
average across 4 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
9-ING-41
Phase 2 · Cancer
Full Press Release Details
2025-ASCO-Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 38) of the GSK-3 inhibitor elraglusib with gemcitabine/nab-paclitaxel (GnP) in metastatic pancreatic ductal adenocarcinoma (mPDAC): application toward patient enrichment Download PDF View Resource
Frequently Asked Questions
What is elraglusib used for?
Elraglusib is a GSK-3 inhibitor being evaluated for treating metastatic pancreatic ductal adenocarcinoma.
How does the trial predict overall survival?
The trial uses machine learning to analyze pre-dose plasma biomarkers to predict overall survival.
What combination therapy is being tested?
The trial tests elraglusib in combination with gemcitabine and nab-paclitaxel.
What is the goal of patient enrichment in this study?
The goal is to improve patient selection for treatment to enhance outcomes.